BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richards KA, Moritzky S, Shannon I, Fitzgerald T, Yang H, Branche A, Topham DJ, Treanor JJ, Nayak J, Sant AJ. Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. NPJ Vaccines 2020;5:77. [PMID: 32884842 DOI: 10.1038/s41541-020-00227-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Barman S, Borriello F, Brook B, Pietrasanta C, De Leon M, Sweitzer C, Menon M, van Haren SD, Soni D, Saito Y, Nanishi E, Yi S, Bobbala S, Levy O, Scott EA, Dowling DJ. Shaping Neonatal Immunization by Tuning the Delivery of Synergistic Adjuvants via Nanocarriers. ACS Chem Biol 2022. [PMID: 36028220 DOI: 10.1021/acschembio.2c00497] [Reference Citation Analysis]
2 Marco-Dufort B, Janczy JR, Hu T, Lütolf M, Gatti F, Wolf M, Woods A, Tetter S, Sridhar BV, Tibbitt MW. Thermal stabilization of diverse biologics using reversible hydrogels. Sci Adv 2022;8:eabo0502. [PMID: 35930644 DOI: 10.1126/sciadv.abo0502] [Reference Citation Analysis]
3 Quinlan EJ, Chubet R, Leonardi P. A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology. Hum Vaccin Immunother 2022;:1-6. [PMID: 35801956 DOI: 10.1080/21645515.2022.2062971] [Reference Citation Analysis]
4 Carascal MB, Pavon RDN, Rivera WL. Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. Front Immunol 2022;13:878943. [PMID: 35663997 DOI: 10.3389/fimmu.2022.878943] [Reference Citation Analysis]
5 Zhuang X, Chen L, Yang S, Xia S, Xu Z, Zhang T, Zeng B, Yu T, Yu N, Wang W, Lu H, Tian M, Jin N. R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice. Front Immunol 2022;13:836274. [DOI: 10.3389/fimmu.2022.836274] [Reference Citation Analysis]
6 Deviatkin AA, Simonov RA, Trutneva KA, Maznina AA, Khavina EM, Volchkov PY. Universal Flu mRNA Vaccine: Promises, Prospects, and Problems. Vaccines 2022;10:709. [DOI: 10.3390/vaccines10050709] [Reference Citation Analysis]
7 Barman S, Soni D, Brook B, Nanishi E, Dowling DJ. Precision Vaccine Development: Cues From Natural Immunity. Front Immunol 2021;12:662218. [PMID: 35222350 DOI: 10.3389/fimmu.2021.662218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
8 Dong C, Wang Y, Zhu W, Ma Y, Kim J, Wei L, Gonzalez GX, Wang BZ. Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice. ACS Appl Mater Interfaces 2022. [PMID: 35084819 DOI: 10.1021/acsami.1c19192] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Matić Z, Šantak M. Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol 2021. [PMID: 34889981 DOI: 10.1007/s00253-021-11713-0] [Reference Citation Analysis]
10 Bansal A, Trieu MC, Mohn KGI, Cox RJ. Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review. Front Immunol 2021;12:744774. [PMID: 34691051 DOI: 10.3389/fimmu.2021.744774] [Reference Citation Analysis]
11 Zhang R, Hung IF. Approaches in broadening the neutralizing antibody response of the influenza vaccine. Expert Rev Vaccines 2021;20:1539-47. [PMID: 34549677 DOI: 10.1080/14760584.2021.1984887] [Reference Citation Analysis]
12 Nelson SA, Dileepan T, Rasley A, Jenkins MK, Fischer NO, Sant AJ. Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge. J Virol 2021;95:e0084121. [PMID: 34076479 DOI: 10.1128/JVI.00841-21] [Reference Citation Analysis]
13 Richards KA, Glover M, Crawford JC, Thomas PG, White C, Sant AJ. Circulating CD4 T Cells Elicited by Endemic Coronaviruses Display Vast Disparities in Abundance and Functional Potential Linked to Antigen Specificity and Age. J Infect Dis 2021;223:1555-63. [PMID: 33556959 DOI: 10.1093/infdis/jiab076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sekiya T, Ohno M, Nomura N, Handabile C, Shingai M, Jackson DC, Brown LE, Kida H. Selecting and Using the Appropriate Influenza Vaccine for Each Individual. Viruses 2021;13:971. [PMID: 34073843 DOI: 10.3390/v13060971] [Reference Citation Analysis]
15 Yu ED, Grifoni A, Sutherland A, Voic H, Wang E, Frazier A, Jimenez-Truque N, Yoder S, Welsh S, Wooden S, Koff W, Creech B, Sette A, da Silva Antunes R. Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine. Vaccines (Basel) 2021;9:426. [PMID: 33922875 DOI: 10.3390/vaccines9050426] [Reference Citation Analysis]
16 Nagashima KA, Mousa JJ. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine. Viruses 2021;13:546. [PMID: 33805245 DOI: 10.3390/v13040546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Radvak P, Kosikova M, Kuo YC, Li X, Garner R, Schmeisser F, Kosik I, Ye Z, Weir JP, Yewdell JW, Xie H. Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses. NPJ Vaccines 2021;6:30. [PMID: 33637737 DOI: 10.1038/s41541-021-00295-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]